New Therapy for Spinal Cord Injuries
Total ReCord, Inc., an early-stage company founded for the specific purpose of developing and commercializing new therapies for neurodegenerative diseases, plans to begin clinical trials in early 2006 with a new treatment for patients with spinal cord injuries.
RMx(TM), Total ReCord's lead product, is a new non-cellular, non-drug based class of biotherapeutics that draws on the body's natural regenerative processes to stimulate the growth of new central nervous system tissue. RMx's regenerative matrix is a new method of treatment for spinal cord injuries that has shown promising results in preclinical studies in animal models. Total ReCord has created RMx based on the principle of suppressing certain wound healing processes that interfere with central nervous system (CNS) tissue regeneration, while enhancing the desirable traits of these processes.
RMx first works to clean out the site of damaged tissue and allow for new cell growth. It then slows the development of scar tissue that can inhibit the regeneration of surviving axons while simultaneously promoting new blood vessel formation. Both of these processes are crucial for the formation of new, healthy CNS tissue. Furthermore, RMx has certain stimulatory effects on the formation and elongation of new neurites. After this new tissue is grown, it can be trained to function in the body to restore movement, even weight-bearing steps in patients with spinal cord injuries.
In pre-clinical studies, animals that had experienced traumatic damage to their spinal cords and were initially completely paralyzed were soon able to move about after treatment with RMx. In most cases, they were able to make weight-bearing steps. Total ReCord is confident that the human implants that have been successfully used in their animal studies will be effective in treating patients with spinal cord injuries. However, the extent of recovery that can be achieved with RMx in human patients will only become evident after the human clinical studies. RMx has also been found to have no toxic side-effects in animals.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
